Skip to main content

Advertisement

Table 2 Summary of studies reporting SLN procedures for cutaneous squamous cell carcinoma.

From: Sentinel lymph node biopsy for high-risk cutaneous squamous cell carcinoma: clinical experience and review of literature

Author, year # SCC cases Location SLN results and histological methods Adjuvant Treatment Disease Recurrence
Stadelmann, 1997 [36] 1 Extremity 1/1 (100%), H&E LND LR (n = 1, +SLN)
Weisberg, 2000 [37] 1 Head 0/1 (0%), H&E and IHC XRT none
Altinyollar, 2002 [23] 20 Head 3/18 (17%), H&E LND N/A
Reschly, 2003 [10] 9 Head, Truncal/Extremity 4/9 (44%), H&E and IHC LND (n = 3), XRT (n = 1) LR (n = 1, +SLN), DR (n = 1, +SLN)
Michl, 2003 [24] 9 Head, Truncal/Extremity 2/9 (22%), H&E and IHC LND + CTX/XRT (n = 2) DR (n = 1, +SLN)
Eastman, 2004 [25] 6 Extremity 4/6 (67%). H&E and IHC N/A N/A
Ozcelik, 2004 [38] 1 Extremity 0/1 (0%), H&E none none
Wagner, 2004 [26] 12 Head, Truncal/Extremity 2/12 (17%), H&E XRT (n = 2) none
Hatta, 2005 [34] 4 Extremity 0/4 (0%), H&E and IHC N/A N/A
Perez-Naranjo, 2005 [39] 1 Extremity 0/1 (0%), N/A none none
Nouri, 2006 [27] 15 Head 1/15 (6.7%), H&E and IHC LND (n = 4) none
Mullen, 2006 [9] 14 Truncal/Extremity 0/14 (0%), H&E + IHC none LR (n = 2, -SLN) NR (n = 1, -SLN)
Sahn, 2007 [29] 9 Head, Truncal/Extremity 0/9 (0%), H&E and some IHC XRT (n = 3) NR (n = 1, -SLN) DR (n = 1, -SLN)
Renzi, 2007 [30] 22 Head, Truncal/Extremity 1/22 (5%), H&E and IHC LND (n = 1) DR (n = 1, +SLN)
Kwon, 2010 6 Head, Truncal/Extremity 0/6 (0%), H&E and some IHC. none LR (n = 1, -SLN) DR (n = 1, -SLN)
  1. H&E = hematoxylin and eosin, IHC = immunohistochemistry
  2. LND = lymph node dissection, XRT = radiation therapy, CTX = chemotherapy
  3. LR = local recurrence, NR = nodal recurrence, DR = distant metastases, N/A = not available